Vanderbilt University Medical Center
We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.
Inclusion Criteria: * Males and females of all races between 18 and 65 years of age * Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication. * Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2. * Able and willing to provide informed consent. Exclusion Criteria: * Pregnancy or breast feeding * Current smokers or history of heavy smoking (\>2 packs/day) * History of alcohol or drug abuse * Previous allergic reaction to study medications * Type I diabetes. * Cardiovascular disease other…
Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
Moxonidine
Placebo
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.